Cardiovascular dysfunction in obesity and new diagnostic imaging techniques: the role of noninvasive image methods

José Augusto A Barbosa 1
Alexandre B Rodrigues 1
Cleonice Carvalho C Mota 1
Márcia M Barbosa 2
Ana C Simões e Silva 1
1 Department of Pediatrics, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; 2 EcoCenter, Socor Hospital, Belo Horizonte, Minas Gerais, Brazil

Abstract: Obesity is a major public health problem affecting adults and children in both developed and developing countries. This condition often leads to metabolic syndrome, which increases the risk of cardiovascular disease. A large number of studies have been carried out to understand the pathogenesis of cardiovascular dysfunction in obese patients. Endothelial dysfunction plays a key role in the progression of atherosclerosis and the development of coronary artery disease, hypertension and congestive heart failure. Noninvasive methods in the field of cardiovascular imaging, such as measuring intima-media thickness, flow-mediated dilatation, tissue Doppler, and strain, and strain rate, constitute new tools for the early detection of cardiac and vascular dysfunction. These techniques will certainly enable a better evaluation of initial cardiovascular injury and allow the correct, timely management of obese patients. The present review summarizes the main aspects of cardiovascular dysfunction in obesity and discusses the application of recent noninvasive imaging methods for the early detection of cardiovascular alterations.

Keywords: cardiovascular risk, endothelium dysfunction, obesity, strain and strain rate, tissue Doppler

Introduction

The prevalence of overweight and obesity is increasing at a very high rate, affecting an estimated 300 million individuals worldwide. A number of studies carried out in developing countries report an approximate 20% prevalence of obesity.1–3 The prevalence is even higher in developed countries. In 2007–2008, obesity in the United States was reported to affect 32.21% of male adults and 35.5% of female adults.4,5 Considering the standard definition for overweight and obesity in the pediatric population (2 to 19 years of age), 11.9% were at or above the 97th percentile of the body mass index (BMI), 16.9% were at or above the 95th percentile and 31.7% were at or above the 85th percentile.6–8 Childhood obesity increases the risk of obesity in adulthood tenfold and pediatric patients that persistently remain at the 99th BMI percentile are at very high risk for severe adult obesity.9,10

Obesity is commonly associated with a combination of comorbidities, which collectively comprise metabolic syndrome. In 1998, the World Health Organization published a definition for metabolic syndrome that includes insulin resistance, raised plasma triglycerides, low high-density lipoprotein, central obesity or a BMI greater than 30 kg/m² for adults and above the 95th percentile for children and adolescents, microalbuminuria (>20 µg/min) or elevated albumin-to-creatinine ratio (≥30 mg/g) and hypertension.11,12 Recently, a number of other clinical and laboratory features
have been associated with metabolic syndrome, such as nonalcoholic fatty liver disease, polycystic ovarian syndrome, atherosclerosis, proinflammatory state and oxidative stress. Moreover, body measurements, such as the waist-to-hip ratio and waist circumference, seem to predict the risk of mortality better than the BMI.12,13

Cardiovascular complications associated with obesity contribute to high rates of morbidity and mortality. Hypertension is three to five times more common in obese subjects in comparison to individuals within the ideal weight range.14 All components of metabolic syndrome are independent predictors of cardiovascular events, such as stroke, cardiomyopathy, coronary artery disease, myocardial infarction, congestive heart failure and sudden cardiac death.15 Central (mesenteric and omental) obesity is highly correlated to the risk of cardiovascular disease.16-18 The risk of death among obese individuals (BMI > 30 kg/m²) is two to three times higher than nonobese individuals and the severely obese individuals (BMI > 35 kg/m²) have a 5-to-20-year decrease in life expectancy in comparison to nonobese individuals matched for age and gender.14,16

The present review summarizes the main aspects of cardiovascular dysfunction in obesity and discusses the application of recent noninvasive imaging methods in this context.

**Endothelial dysfunction in obesity**

Endothelial dysfunction is associated with a large number of clinical conditions and laboratorial alterations, including diabetes mellitus, hypercholesterolemia, hypertension, insulin resistance, advanced age and obesity.19 Adipose tissue plays a key role in the development of endothelial dysfunction in obese patients.20 An increase in fat mass increases the size and number of adipocytes. Changes associated with adipocyte hypertrophy seem to produce cell dysfunction. An excessive amount of lipid stored in adipocytes leads to functional abnormalities of the endoplasmic reticulum and mitochondria, which, in turn, contribute to intracellular and systemic disorders such as the stimulation of a proinflammatory state, insulin resistance, and high production of free fatty acids (FFAs).21 FFAs accumulate in nonadipose tissue and cause an overproduction of metabolic toxins. Both effects impair insulin signaling and glucose tolerance.22 Nonalcoholic fatty liver disease also plays a very important role in this process.23

In addition, chronic subclinical inflammation associated with visceral and central adiposity often occurs in patients with metabolic syndrome. The major mediators responsible for the balance between proinflammatory and anti-inflammatory pathways are C-reactive protein (CRP), leptin, tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), serum retinol-binding protein 4 (sRBP-4), plasminogen activator inhibitor 1 (PAI-1), nitric oxide (NO), and adiponectin.21,24-27 Fat in the liver also represents a site beyond adipose tissue that independently contributes to the synthesis of inflammatory mediators such as CRP, IL-6 and PAI-1, which are increased in nonalcoholic fatty liver disease.23,28 The predominance of inflammatory mediators in obese patients also contributes to endothelial dysfunction.

CRP is predominantly produced by the liver in response to IL-6 and is chronically elevated in metabolic syndrome. CRP levels are positively correlated with BMI and visceral fat accumulation.29 CRP inhibits the formation of NO by endothelial cells. The lack of NO promotes vasoconstriction, leukocyte adherence, platelet activation, oxidation, and thrombosis, thereby leading to endothelial dysfunction and arterial hypertension.21,24 High levels of CRP are also predictive of atherothrombotic events.26

Leptin is secreted by adipose tissue. This secretion is directly proportional to adipose tissue mass. Leptin receptors are mainly expressed in the hypothalamus and brainstem neuronal circuit and control satiety, energy expenditure, and neuroendocrine functions. Obese patients have elevated levels of endogenous leptin that fail to suppress appetite, thus characterizing a leptin-resistant state. High levels of leptin have been linked to vasculopathy via obesity associated with hypertension.20,25,30 High leptin levels are also associated with insulin resistance and correlated with atherosclerosis and coronary artery calcifications.31,32

TNF-α is a proinflammatory cytokine whose expression is elevated in obese adipose tissue. This cytokine is mainly produced from macrophages within the adipose tissue as well as adipocytes themselves.21,33 There is a strong relationship between TNF-α and the effect of the lipoprotein lipase, which is responsible for the breakdown of circulating triglycerides and very-low-density cholesterol. In metabolic syndrome, there is an increase in macrophage TNF-α expression and a decrease in the effect of lipoprotein lipase, thereby causing hypertriglyceridemia. TNF-α impairs insulin signaling by an increase in circulating FFAs, which induces insulin resistance. TNF-α also plays a role in stimulating the expression of other inflammatory mediators, such as IL-6, and reduces the expression of anti-inflammatory mediators, such as adiponectin.20,22 Furthermore, TNF-α induces insulin resistance through the downregulation of the tyrosine kinase activity of insulin receptors and the serine phosphorylation...
of insulin substrate 1, which converts this protein into an insulin-receptor inhibitor in adipose tissue.\textsuperscript{34} TNF-\(\alpha\) also activates transcription nuclear factor kappa beta (NF-\(\kappa\Bb\)), which induces inflammatory changes within the vessel wall.\textsuperscript{33,36} TNF-\(\alpha\) is a proinflammatory cytokine that plays a very important role in vascular dysfunction in obese patients.

sRBP-4 is a circulating protein of the lipocalin family associated with visceral adiposity and insulin resistance. sRBP-4 is secreted by the liver and adipocytes, reaching high concentrations in chronic low-state inflammation.\textsuperscript{39} In mouse models, sRB4 induces insulin resistance in the liver and skeletal muscle.\textsuperscript{35} In humans, a number of studies report an association between sR4, insulin resistance, and type 2 diabetes.\textsuperscript{21}

PAI-1 is a member of the serine protease inhibitor family and is the primary inhibitor of fibrinolysis. It is secreted mainly by platelets and vascular endothelium and is also produced by adipocyte cells. Plasma PAI-1 is elevated in individuals with obesity and plays a key role in promoting thrombus formation following the rupture of atherosclerotic plaque.\textsuperscript{25,37}

NO has a large number of antiatherogenesis actions, including induction of potent vasodilatation, capacity to diminish the adhesion of monocytes and the aggregation of platelets to the endothelium, and has an inhibitory effect on the proliferation of smooth muscle cells.\textsuperscript{38} Reduced synthesis of NO is also an early inducer of obesity. Insulin resistance and the chronic rise in plasma glucose enhance the expression of glutamine fructose 6 phosphate transaminase, which in turn stimulates the production of glucosamine, thereby favoring oxidative stress in endothelial cells.\textsuperscript{39,40} TNF-\(\alpha\) also plays a role in this process as it inhibits endothelium-dependent vasorelaxation by increasing the generation of reactive oxygen species, which activate NF-\(\kappa\Bb\), a transcription regulator of molecular adhesion important to the control of inflammatory and oxidative states of vascular endothelial cells.\textsuperscript{19,41–45}

Adiponectin is a protein with 247 amino acids produced by adipocytes (adipokine) that exerts potent endothelium-protective effects.\textsuperscript{44} Adiponectin levels are significantly lower in obese individuals in comparison to nonobese individuals and have been negatively correlated with percentage of body fat, waist-to-hip ratio and abdominal fat.\textsuperscript{43} Serum adiponectin circulates in three forms: low-, middle-, and high-molecular weight, which is the most active form. Adiponectin receptors are expressed in muscle, liver, and fat cells.\textsuperscript{46} Low concentrations of adiponectin contribute to a variety of obesity-related diseases, including diabetes, vascular abnormalities, and heart disease, and are inversely associated with CRP and TNF-\(\alpha\) levels.\textsuperscript{45,46} The main effects of adiponectin are the regulation of glucose metabolism, the improvement of sensitivity to insulin, the reduction in atherosclerotic lesions, the inhibition of monocyte adhesion to endothelial cells, the suppression of macrophage transformation into foam cells, and the decrease in the proliferation and migration of smooth muscle cells.\textsuperscript{35} It also increases endothelial NO production, thereby enhancing vasodilatation and inhibiting platelet aggregation. Adiponectin influences cardiac remodeling by suppressing pathological heart growth and is believed to have a protective effect on ischemic/reperfusion cardiac injury.\textsuperscript{22,44,45,47–49} Nonalcoholic fatty liver disease has been also associated to low serum levels of adiponectin.\textsuperscript{23}

**Atherosclerosis and coronary artery disease in obesity**

Obesity is an independent predictor of coronary artery disease. Among men aged under 50 years, obese individuals have twice the risk of coronary disease and obese women of a similar age have a 2.4-fold greater risk.\textsuperscript{50}

Obesity results in increased deposition of perivascular fat around the heart and its major branches. This increased adipose tissue surrounding the blood vessels causes the overproduction of proinflammatory and profibrotic cytokines, leading to inflammation and atherosclerosis, with a consequent increase in intima-media thickness and decrease in arterial distensibility.\textsuperscript{17} The activation of the rennin–angiotensin–aldosterone system and of the sympathetic nervous system in metabolic syndrome leads to an increase in coronary vasoconstriction, which significantly contributes to the imbalance between coronary blood flow and myocardial metabolism.\textsuperscript{15} Experimental studies have demonstrated that, even in the early stage of obesity, there is a reduction in coronary endothelium-dependent vasorelaxation.\textsuperscript{51}

Acute coronary syndromes are usually triggered by the rupture or erosion of atheromatous plaque; when the plaque ruptures, endothelial tissue factor is exposed to the blood and activates the coagulation cascade, causing thrombus formation.\textsuperscript{29}

**Arterial hypertension in obesity**

The prevalence of hypertension in obese patients in the United States is on the rise and individuals with a BMI greater than 40 have a sevenfold greater likelihood of being hypertensive.\textsuperscript{52} Obesity in children and adolescents also leads to hypertension. Chioiero and colleagues conducted a prevalence study on hypertension and found that this condition was attributed to overweight or obesity in 37% of cases.\textsuperscript{53} In Switzerland, Maggio and colleagues found an
association between obese children and systolic hypertension in 47.6% of patients as well as an increase in left ventricular mass partially caused by high systemic blood pressure.\(^{54}\) Obese children have a tenfold greater risk of developing hypertension as young adults than nonobese children and a continuous relationship between BMI and arterial pressure has been reported.\(^{55,56}\) One study reports that 10 kg of excess body weight is associated with a 3.0-mmHg higher systolic and 2.3-mmHg higher diastolic blood pressure.\(^{56}\) Stabouli and colleagues\(^{57}\) reported that obese adolescents have higher blood pressure and greater carotid artery intima-media thickness in comparison to nonobese pairs.

The mechanism of hypertension in metabolic syndrome is highly complex. The obese-related inflammatory state is one of the factors probably responsible for hypertension.\(^{58}\) The inflammatory state leads to hyperinsulinemia, insulin resistance, dyslipidemia, and oxidative stress, along with serious damage to organ systems. Obese patients have increased systemic blood volume. The normal compensatory response to an elevated cardiac output, which should be a drop in peripheral vascular resistance, is hindered in obese patients with hypertension, exhibiting an inappropriately normal total peripheral resistance.\(^{59}\) Studies have shown that increased sympathetic activity and hypooactivity of the parasympathetic nervous system, even in children, also results in an increased incidence of hypertension by augmenting sodium retention and vascular smooth muscle hypertrophy, affecting glucose delivery to the muscles and postprandial lipid clearance.\(^{60–62}\) The increasing of the FFAs, along with increased levels of circulating glucose, promotes insulin secretion by the pancreas, resulting in hyperinsulinemia. These events, in turn, can cause increased sodium reabsorption and sympathetic nervous system activity, with subsequent development or worsening of hypertension.\(^{18}\)

The activation of the rennin–angiotensin–aldosterone system also significantly contributes to hypertension in obese patients.\(^{35,60}\) Adipose tissue is able to synthesize the components of the rennin–angiotensin–aldosterone system.\(^{35,60}\) In this regard, the formation of angiotensin II in the adipose tissue enhances the production of proinflammatory and profibrotic cytokines\(^{55,50}\) and stimulates per se vasoconstriction, smooth muscle vascular cell proliferation, and endothelial dysfunction.\(^{58}\) Beside angiotensin II, the elevation of plasma levels of aldosterone might promote myocardial tissue growth.\(^{60}\)

**Left ventricular involvement in obesity**

Cardiac involvement in obesity has been frequently reported in the literature, and the most frequently found abnormalities are: increased left ventricular diameters and mass, eccentric hypertrophy, diastolic dysfunction and, occasionally, systolic dysfunction and heart failure.\(^{53–55}\) Indeed, obesity has been linked to a spectrum of minor cardiovascular abnormalities, ranging from a hyperdynamic circulation to subclinical structural changes.

**Congestive heart failure in obesity**

Excess weight has been linked to heart failure and mortality. For each increment of one above 30 on the BMI, the risk of developing heart failure increases 5% in men and 7% in women.\(^{50}\) Obesity has been associated with systolic and diastolic heart dysfunction. In a cross-sectional study, Ammar and colleagues found a strong correlation between left ventricular systolic and diastolic dysfunction and central obesity, as measured by the waist-to-hip ratio.\(^{66}\)

Studies have documented a better chance of survival from cardiac events in patients with decreased left ventricular ejection fraction and a higher BMI in comparison to those with a lower BMI, which is known as the “obesity paradox”. The pathophysiology of the obesity paradox is unknown and some authors state that this paradox could be explained by an additional disease in patients with low BMI, such as lung disease.\(^{67}\) Kapoor and Heidenreich have recently reported that the mortality rate in cardiac events is increased in obese patients with a BMI of 45 or more in comparison to lean peers.\(^{68}\) Moreover, among a cohort of 1,790 patients, Frankenstein and colleagues found that the obesity paradox in patients with stable heart failure did not persist after matching for clinical characteristics and disease severity.\(^{59}\)

There are studies confirming the relationship between left atrial size and the development of adverse cardiovascular outcomes and those describing a strong correlation between BMI and atrial fibrillation, which deteriorates the cardiac failure.\(^{70,71}\)

**The role of noninvasive image methods in obesity**

Metabolic syndrome and its association with vascular and cardiac dysfunction is currently the greatest cause of mortality and this situation is expected to continue in the future.\(^{72}\) Noninvasive techniques for evaluating vascular dysfunction such as flow-mediated dilatation, pulse wave velocity, carotid intima-media thickness, and transient elastography to evaluate fatty liver disease\(^{73}\) are very good surrogate vascular markers. For the early assessment of cardiac dysfunction, tissue Doppler, strain, and strain rate have proven useful in patients with obesity and other morbidities.
Vascular Health and Risk Management downloaded from https://www.dovepress.com/ by 54.191.40.80 on 31-May-2017
For personal use only.
enlargement of the atria is associated with obesity and it serves as a reservoir that receives blood from the pulmonary venous return and stores energy in the form of pressure. During the early phase of ventricular diastole, the left atrium operates as a conduit for transferring blood into the left ventricle following the opening of the mitral valve due to a pressure gradient and through which blood flows passively from the pulmonary veins into the left ventricle; the contractile function of the left atrium, during the late phase of diastole, increases the left ventricular stroke volume by nearly 20%.71

Left atrial size is an expression of chronic left ventricular filling pressures. Early studies had demonstrated the value of left ventricular diameter in predicting prognosis of cardiac diseases and in the development of atrial fibrillation. More recently, left atrial volume has been shown to be an important and more accurate measurement of left atrial size and this measurement, indexed to body surface area, has been used to predict prognosis in several heart diseases.71,98,99 Although left atrial volume seems to correlate with diastolic filling pressures, accurate and direct measurements of the left atrial function have not been established.

Enlargement of the atria is associated with obesity and has been also linked with an increased risk of mortality.100 Using standard echocardiography techniques, Hirschler and

Table 1 Recent studies using tissue Doppler, strain, and strain rate to evaluate cardiac function in obese subjects

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Study population</th>
<th>Cutoffs of BMI (kg/m²) or waist circumference (cm)</th>
<th>Results</th>
<th>Commentary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metha et al59</td>
<td>Obese children (n = 25)</td>
<td>BMI &gt; 25 (independent of age)</td>
<td>Decrease in diastolic function</td>
<td>Healthy obese children with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 13.8 ± 1.9 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 14.4 ± 2.1 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wong et al72</td>
<td>Obese adults (n = 109)</td>
<td>Groups</td>
<td>Left ventricular systolic and diastolic dysfunction</td>
<td>Healthy obese children with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 46 ± 10 years</td>
<td>1-BMI: 25–29.9 overweight</td>
<td>in patients with moderate to severe obesity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overweight: 45 ± 11 years</td>
<td>2-BMI: 30–34.9 mild obesity</td>
<td>Insulin levels were a significant predictor of systolic and diastolic heart dysfunction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild obesity: 42 ± 8 years</td>
<td>3-BMI &gt; 35 severe obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe obesity: 43 ± 10 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Salvo et al105</td>
<td>Obese children (n = 150)</td>
<td>Percentile &gt;97th for sex and age (according to CDC)</td>
<td>Systolic dysfunction in both right and left ventricle</td>
<td>Healthy obese children with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 12 ± 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 12 ± 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wong et al53</td>
<td>Obese adults (n = 112)</td>
<td>BMI: 25–29.9 overweight</td>
<td>Increase in BMI associated with increased severity of right ventricle dysfunction</td>
<td>Healthy obese children with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 43 ± 11 years</td>
<td>BMI: 30–34.9 mild obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overweight: 44 ± 10 years</td>
<td>BMI: &gt; 35 severe obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mild obesity: 41 ± 8 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe obesity: 44 ± 13 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorch and Sharkey96</td>
<td>Obese children (n = 53)</td>
<td>Percentile &gt;95th for sex and age (CDC)*</td>
<td>Systolic and diastolic dysfunction of left ventricle</td>
<td>Retrospective study</td>
</tr>
<tr>
<td></td>
<td>Control: 13.9 ± 2.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 13.8 ± 2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumuklu et al106</td>
<td>Obese adults (n = 33)</td>
<td>BMI: 30–34.9 moderate obesity</td>
<td>Systolic left ventricular dysfunction</td>
<td>Healthy obese subjects with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 43 ± 11</td>
<td>BMI: &gt; 35 severe obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderate obesity: 42 ± 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe obesity: 42 ± 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Salvo et al104</td>
<td>Obese children (n = 150)</td>
<td>Percentile &gt;97th for sex and age (according to CDC)</td>
<td>Reduced left and right atrial myocardial deformation</td>
<td>Healthy obese children with no comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 12 ± 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 12 ± 3 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sürürçü et al107</td>
<td>Obese adults (n = 25)</td>
<td>BMI ≥ 27</td>
<td>Right and left ventricular systolic and diastolic dysfunction</td>
<td>Tissue Doppler technique and all subjects of the study with normal angiography</td>
</tr>
<tr>
<td></td>
<td>Control: 53 ± 6 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 54 ± 8 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gong et al94</td>
<td>Obese adults (n = 200)</td>
<td>Waist circumference ≥ 90 cm for men and ≥80 cm for women</td>
<td>Left ventricular systolic and diastolic dysfunction</td>
<td>Obese patients with comorbidities including hypertension, dyslipidemia and hyperglycemia</td>
</tr>
<tr>
<td></td>
<td>Control: 49 ± 10 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 50 ± 9 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gulel et al102</td>
<td>Obese adults (n = 37)</td>
<td>BMI ≥ 30 kg/m²</td>
<td>No difference between groups considering left atrial function</td>
<td>No comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 35 ± 5 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 36 ± 11 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orhan et al108</td>
<td>Obese adults (n = 29)</td>
<td>BMI ≥ 30 kg/m²</td>
<td>Left and right ventricular systolic and diastolic dysfunction</td>
<td>No comorbidities</td>
</tr>
<tr>
<td></td>
<td>Control: 47 ± 7 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese: 49 ± 8 years</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CDC, Centers for Disease Control and Prevention.
colleagues concluded that left atrial enlargement is related to abdominal obesity and hypertension in children.\textsuperscript{101} Kosar and colleagues found that obese patients without cardiovascular disease exhibit enlargement of left atrium in standard echocardiography.\textsuperscript{102}

Strain and strain rate methods have emerged as promising methods to evaluate atrial function, but with controversial results. Gulel and colleagues compared left atrial function using color tissue Doppler imaging in adults with a BMI $\geq 30$ kg/m$^2$ versus those with a BMI $< 30$ kg/m$^2$ and found no differences in systolic or diastolic atrial function between groups.\textsuperscript{103} On the other hand, Di Salvo and colleagues studied nonhypertensive children using strain and strain rate and found reduced left and right atrial function in the obese group.\textsuperscript{104} Further studies should be carried out to clarify these controversial results.

In summary, obesity, even without comorbidities, is generally associated with cardiac events. Overt systolic and diastolic dysfunction has been described in obesity. New findings, indicating the occurrence of pre-clinical systolic and diastolic dysfunction, even in young obese patients, suggest that obese patients should be carefully monitored in order to detect incipient dysfunction. Efforts should be made, not only to make obese patients lose weight and control other cardiovascular risk factors, but also to detect incipient atrial and ventricular dysfunction. If these patients should be treated before the development of overt ventricular dysfunction, remains to be established. Table 1 summarizes the most recent studies using tissue Doppler imaging, strain and strain rate to evaluate cardiac function in obese subjects.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


90. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. Dec 2005;18(12):1440–1463.